Share
Glucagon-like peptide-1 receptor agonists (GLP‑1 Ras) — such as semaglutide and liraglutide — are celebrated for producing weight-loss results comparable to bariatric surgery, improving glucose control, and reducing cardiovascular risk. Yet new questions are surfacing about what users may be losing, besides fat. A recent narrative review in the Journal of Clinical Endocrinology & Metabolism warns...
Share
As the prevalence of type 2 diabetes and liver disease continues to increase, so too does the awareness of the bidirectional relationship between these two diseases. Endocrine News speaks to Priyanka Majety, MD, about her recent paper detailing this relationship, and how endocrinologists are uniquely positioned to break the cycle. In her practice, Priyanka Majety,...
Share
A novel AI-powered retina tracker can analyze retinal images with near-perfect accuracy in under one second, according to a study being presented Monday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. The researchers say the findings offer hope for sight-saving screenings for diabetic retinopathy and other eye diseases that are fast, affordable,...
Share
A new study entitled “Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users” published in JAMA Surgery calls into question the current guidelines advising doctors to pause a widely used class of diabetes drugs—sodium-glucose cotransporter 2 inhibitors (SGLT2i) — before surgery. The findings suggest the risk of developing postoperative euglycemic ketoacidosis (eKA), a serious and potentially...
Share
Priyanka Majety, MD, discusses a new, FDA-approved wearable insulin-delivery patch that could potentially improve patients’ insulin adherence as well as their quality of life. Last summer, a wearable patch designed for mealtime insulin delivery (in lieu of traditional injections) received clearance from the U.S. Food and Drug Administration, extending the patch’s wear time from three...
Share
Measuring the circulating abundance of microRNAs is likely as effective as measuring the level of sugar in the blood for determining how a young person with type 2 diabetes will fare, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Jeanie Tryggestad, MD, an associate professor of...
Share
GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed...
Share
Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on...
